Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML
Authors
Keywords
-
Journal
LEUKEMIA
Volume 31, Issue 4, Pages 829-836
Publisher
Springer Nature
Online
2017-01-11
DOI
10.1038/leu.2017.9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia
- (2015) A Burchert et al. LEUKEMIA
- Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
- (2015) N C P Cross et al. LEUKEMIA
- Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms
- (2014) D. Niebel et al. BLOOD
- How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia
- (2014) David M. Ross et al. BRITISH JOURNAL OF HAEMATOLOGY
- Immunology and Immunotherapy of Chronic Myeloid Leukemia
- (2014) Mette Ilander et al. Current Hematologic Malignancy Reports
- Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
- (2013) S. Branford et al. BLOOD
- Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
- (2013) E. Jabbour et al. BLOOD
- Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
- (2013) D. M. Ross et al. BLOOD
- Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV
- (2013) Rüdiger Hehlmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
- (2013) Philippe Rousselot et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go
- (2013) Angela Vasaturo et al. Frontiers in Immunology
- Depletion of Plasmacytoid Dendritic Cells Inhibits Tumor Growth and Prevents Bone Metastasis of Breast Cancer Cells
- (2012) Anandi Sawant et al. JOURNAL OF IMMUNOLOGY
- Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
- (2012) M Talpaz et al. LEUKEMIA
- Standardized definitions of molecular response in chronic myeloid leukemia
- (2012) N C P Cross et al. LEUKEMIA
- Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
- (2012) R A Larson et al. LEUKEMIA
- The PD-1 pathway in tolerance and autoimmunity
- (2010) Loise M. Francisco et al. IMMUNOLOGICAL REVIEWS
- Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia
- (2010) Andreas Burchert et al. JOURNAL OF CLINICAL ONCOLOGY
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- Harmonization of molecular monitoring of CML therapy in Europe
- (2009) M C Müller et al. LEUKEMIA
- Antigen-Presentation Properties of Plasmacytoid Dendritic Cells
- (2008) José A. Villadangos et al. IMMUNITY
- Plasmacytoid Dendritic Cells Mediate Oral Tolerance
- (2008) Anne Goubier et al. IMMUNITY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now